Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
Type:
Application
Filed:
May 7, 2007
Publication date:
December 10, 2009
Applicant:
Isis Phamaceuticals, Inc.
Inventors:
Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric Swayze, Edward Wancewicz
Abstract: Methods for identifying oligonucleotides having a desired activity in vivo are disclosed. In accordance with preferred embodiments, oligonucleotides capable of conferring a desired phenotype are identified. Therapeutic, diagnostic and research methods and compositions employing such oligonucleotides are provided. Prior knowledge of the sequence or structure of a target molecule is generally not required.
Type:
Grant
Filed:
December 2, 1993
Date of Patent:
June 17, 1997
Assignee:
Isis Phamaceuticals, Inc.
Inventors:
Christopher K. Mirabelli, David J. Ecker, Timothy A. Vickers, Debra L. Robertson